Cargando…

Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology

Cystic fibrosis (CF) is an inherited disorder characterized by chronic airway inflammation. microRNAs (miRNAs) are endogenous small RNAs which act on messenger (m) RNA at a post transcriptional level, and there is a growing understanding that altered expression of miRNA is involved in the CF phenoty...

Descripción completa

Detalles Bibliográficos
Autores principales: McKiernan, Paul J, Cunningham, Orla, Greene, Catherine M, Cryan, Sally-Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798151/
https://www.ncbi.nlm.nih.gov/pubmed/24143095
http://dx.doi.org/10.2147/IJN.S47551
_version_ 1782287725607518208
author McKiernan, Paul J
Cunningham, Orla
Greene, Catherine M
Cryan, Sally-Ann
author_facet McKiernan, Paul J
Cunningham, Orla
Greene, Catherine M
Cryan, Sally-Ann
author_sort McKiernan, Paul J
collection PubMed
description Cystic fibrosis (CF) is an inherited disorder characterized by chronic airway inflammation. microRNAs (miRNAs) are endogenous small RNAs which act on messenger (m) RNA at a post transcriptional level, and there is a growing understanding that altered expression of miRNA is involved in the CF phenotype. Modulation of miRNA by replacement using miRNA mimics (premiRs) presents a new therapeutic paradigm for CF, but effective and safe methods of delivery to the CF epithelium are limiting clinical translation. Herein, polymeric nanoparticles are investigated for delivery of miRNA mimics into CF airway epithelial cells, using miR-126 as a proof-of-concept premiR cargo to determine efficiency. Two polymers, polyethyleneimine (PEI) and chitosan, were used to prepare miRNA nanomedicines, characterized for their size, surface (zeta) potential, and RNA complexation efficiency, and screened for delivery and cytotoxicity in CFBE41o- (human F508del cystic fibrosis transmembrane conductance regulator bronchial epithelial) cells using a novel high content analysis method. RNA extraction was carried out 24 hours post transfection, and miR-126 and TOM1 (target of Myb1) expression (a validated miR-126 target) was assessed. Manufacture was optimized to produce small nanoparticles that effectively complexed miRNA. Using high content analysis, PEI-based nanoparticles were more effective than chitosan-based nanoparticles in facilitating uptake of miRNA into CFBE41o- cells and this was confirmed in miR-126 assays. PEI-premiR-126 nanoparticles at low nitrogen/phosphate (N/P) ratios resulted in significant knockdown of TOM1 in CFBE41o- cells, with the most significant reduction of 66% in TOM1 expression elicited at an N/P ratio of 1:1 while chitosan-based miR-126 nanomedicines failed to facilitate statistically significant knockdown of TOM1 and both nanoparticles appeared relatively nontoxic. miRNA nanomedicine uptake can be qualitatively and quantitatively assessed rapidly by high content analysis and is highly polymer-dependent but, interestingly, there is not a direct correlation between the levels of miRNA uptake and the downstream gene knockdown. Polymeric nanoparticles can deliver premiRs effectively to CFBEs in order to modulate gene expression but must be tailored specifically for miRNA delivery.
format Online
Article
Text
id pubmed-3798151
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-37981512013-10-18 Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology McKiernan, Paul J Cunningham, Orla Greene, Catherine M Cryan, Sally-Ann Int J Nanomedicine Original Research Cystic fibrosis (CF) is an inherited disorder characterized by chronic airway inflammation. microRNAs (miRNAs) are endogenous small RNAs which act on messenger (m) RNA at a post transcriptional level, and there is a growing understanding that altered expression of miRNA is involved in the CF phenotype. Modulation of miRNA by replacement using miRNA mimics (premiRs) presents a new therapeutic paradigm for CF, but effective and safe methods of delivery to the CF epithelium are limiting clinical translation. Herein, polymeric nanoparticles are investigated for delivery of miRNA mimics into CF airway epithelial cells, using miR-126 as a proof-of-concept premiR cargo to determine efficiency. Two polymers, polyethyleneimine (PEI) and chitosan, were used to prepare miRNA nanomedicines, characterized for their size, surface (zeta) potential, and RNA complexation efficiency, and screened for delivery and cytotoxicity in CFBE41o- (human F508del cystic fibrosis transmembrane conductance regulator bronchial epithelial) cells using a novel high content analysis method. RNA extraction was carried out 24 hours post transfection, and miR-126 and TOM1 (target of Myb1) expression (a validated miR-126 target) was assessed. Manufacture was optimized to produce small nanoparticles that effectively complexed miRNA. Using high content analysis, PEI-based nanoparticles were more effective than chitosan-based nanoparticles in facilitating uptake of miRNA into CFBE41o- cells and this was confirmed in miR-126 assays. PEI-premiR-126 nanoparticles at low nitrogen/phosphate (N/P) ratios resulted in significant knockdown of TOM1 in CFBE41o- cells, with the most significant reduction of 66% in TOM1 expression elicited at an N/P ratio of 1:1 while chitosan-based miR-126 nanomedicines failed to facilitate statistically significant knockdown of TOM1 and both nanoparticles appeared relatively nontoxic. miRNA nanomedicine uptake can be qualitatively and quantitatively assessed rapidly by high content analysis and is highly polymer-dependent but, interestingly, there is not a direct correlation between the levels of miRNA uptake and the downstream gene knockdown. Polymeric nanoparticles can deliver premiRs effectively to CFBEs in order to modulate gene expression but must be tailored specifically for miRNA delivery. Dove Medical Press 2013 2013-10-11 /pmc/articles/PMC3798151/ /pubmed/24143095 http://dx.doi.org/10.2147/IJN.S47551 Text en © 2013 McKiernan et al. This work is published by Dove Medical Press Ltd, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Ltd, provided the work is properly attributed.
spellingShingle Original Research
McKiernan, Paul J
Cunningham, Orla
Greene, Catherine M
Cryan, Sally-Ann
Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology
title Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology
title_full Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology
title_fullStr Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology
title_full_unstemmed Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology
title_short Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology
title_sort targeting mirna-based medicines to cystic fibrosis airway epithelial cells using nanotechnology
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798151/
https://www.ncbi.nlm.nih.gov/pubmed/24143095
http://dx.doi.org/10.2147/IJN.S47551
work_keys_str_mv AT mckiernanpaulj targetingmirnabasedmedicinestocysticfibrosisairwayepithelialcellsusingnanotechnology
AT cunninghamorla targetingmirnabasedmedicinestocysticfibrosisairwayepithelialcellsusingnanotechnology
AT greenecatherinem targetingmirnabasedmedicinestocysticfibrosisairwayepithelialcellsusingnanotechnology
AT cryansallyann targetingmirnabasedmedicinestocysticfibrosisairwayepithelialcellsusingnanotechnology